G6PD and heme pigmentinduced ATN AM Report - PowerPoint PPT Presentation

1 / 18
About This Presentation
Title:

G6PD and heme pigmentinduced ATN AM Report

Description:

An inherited condition in which patients are excessively susceptible to the ... It is the most common ... Ann Trop Paediatrics. 1993; 13:391. utdol.com ... – PowerPoint PPT presentation

Number of Views:243
Avg rating:3.0/5.0
Slides: 19
Provided by: Goog197
Category:

less

Transcript and Presenter's Notes

Title: G6PD and heme pigmentinduced ATN AM Report


1
G6PD and heme pigment-induced ATNAM Report
  • Emily Chang
  • September 5, 2008

2
What is it?
An inherited condition in which patients are
excessively susceptible to the development of
hemolytic anemia.  It is the most common
enzymatic disorder of RBCs in humans.   Affected
individuals lack the ability to tolerate
biochemical oxidative stress, and red cell
hemolysis is the most important clinical
consequence. First noted in African-American
soldiers who developed acute hemolytic anemia
with hemoglobinuria following primaquine
ingestion.
3
WHO working groups
  • Class I severely deficient, associated with
    chronic nonspherocytic hemolytic anemia
  •  
  • Class II severely deficient (1-10 residual
    activity), associated with acute intermittent
    hemolytic anemia (G6PD Mediterranean)
  •  
  • Class III moderately deficient (10-60 residual
    activity) - intermittent hemolysis usu assoc with
    infection or drugs (G6PD A)
  • Class IV normal activity (60-150)
  • Class V increased activity (gt150)

4
Who gets it?
An X-linked disorder that therefore typically
affects men. Over 400 million people worldwide
affected with highest prevalence in individuals
of African, Mediterranean and Asian
heritage.   Since this is an X-linked gene,
prevalence among females is higher but they are
generally asymptomatic. Confers anti-malarial
protection - unknown mechanism
5
How does it present?
  • Usually asymptomatic but can also vary from
    episodic anemia to chronic hemolysis.  The
    presentation depends on the biochemistry of the
    variant.  There are over 500 different mutations
    identified thus far.
  • acute hemolytic anemia
  • congenital nonsperocytic hemolytic anemia
  • neonatal hyperbilirubinemia
  • favism

6
Acute hemolytic anemia
  • Asymptomatic at steady state without anemia or
    abnormal morphology.
  • Sudden destruction of deficient erythrocytes 2-4
    days after offending "event" leads to jaundice,
    pallor, dark urine, /- back pain.  Abrupt drop
    in H/H to lt4 g/dL and PBS with microspherocytes,
    cell fragments or bite cells.  Sequestration of
    damaged red cells in liver and spleen.
  • Increase in reticulocytes within 5 days, maximal
    at 7-10 days with reversal of anemia even without
    removal of offending drug.
  • In G6PD Mediterranean, hemolysis more severe and
    can continue even after drug d/c'd.

7
Congenital nonspherocytic hemolytic anemia
  • Class I variants in whom lifelong hemolysis
    occurs in absence of preceding event.
  • Functional defect is so severe that RBCs cannot
    withstand normal stresses in the circulation.
  • Anemia and jaundice usually noted in newborn
    period.
  • Mild to moderate anemia (8-10 g/dL) with rare
    pallor, SM and intermittent icterus. 
    Erythropoietic capacity compensates.
  • In severely deficient, neutrophil dysfunction due
    to G6PD deficiency leads to impaired neutrophil
    activity and recurrent infections with
    catalase-positive organisms.

8
Favism
  • Results from ingestion of fava beans.
  • Peak incidence April/May coincident with harvest
    time.
  • Usually male children, ages 1-5.
  • 5-24 hours after ingestion - HA, nausea, back
    pain, chills, fever, jaundice and
    hemoglobinuria.  Acute fall in hemoglobin
    requiring transfusion.
  • Most commonly seen with G6PD Mediterranean
    variant.

9
How does it work?
G6PD is required by all cells to protect from
damage by oxidation. It catalyses the first step
in the HMP pathway (glucose-6-P oxidized to
6-phosphogluconate) which is linked to the
reduction of NADP to NADPH, which is used to
generate reduced glutathione.    For the red
cell, this is the sole source of protection
against oxidant damage in the form of free
radicals generated by the conversion of oxy- to
deoxyhemoglobin and by peroxides generated by
phagocytosing granulocytes.   
10
cont'd
  • Normal red cells generate NADPH in response to
    oxidant stress this capacity is impaired in
    patients with G6PD deficiency. Failure to
    withstand oxidant stress damage to sulphydryl
    groups in hemoglobin and the red cell membrane
    causes hemolysis. 
  •  
  • Cells in other tissues and organs have alternate
    pathways for the generation of NADPH and can
    withstand such oxidant stress. But not so in the
    simple RBC. 
  •  
  • The activity of all red cell enzymes, including
    G6PD, is highest in young red cells
    (reticulocytes), and progressively declines as
    the cell ages.

11
Biochemical pathway the Hexose monophosphate
shunt
12
Precipitants
  • Infections (salmonella, E.coli, beta-hemolytic
    strep, rickettsiae, viral hepatitis) 
  • Medications
  • anti-malarials (primaquine)
  • anti-bacterials (dapsone, furazolidone,
    nitrofurantoin, sulfonamides, quinolones)
  • others (acetenalide, methylene blue, naphthalene
    in moth balls and henna, toluidine blue,
    trinitrotoluene, rasburicase, vitamin k
    derivatives)
  • possible association (phenazopyridine, ASA,
    doxorubicin, flutamide, probenecid,
    sulfasalazine, aminopyrine, aminosalycilic acid,
    acetylphenylhydrazine)
  • Metabolic abnormalities (DKA) 

13
Laboratory diagnosis
  • CBC
  • retic profile
  • urinalysis
  • LDH/haptoglobin
  • fractionated bilirubin
  • blood smear with stains for Heinz bodies
  •  
  • G6PD fluroescent spot test
  • Detects deficient production of NADPH from NADP.
    In this test NADPH is fluorescent and its absence
    (due to G6PD deficiency) results in lack of
    fluorescence.
  • G6PD spectrophotometry to detect level of
    activity
  • genetic test for variants 

14
Peripheral Blood Smear
15
How do you treat it?
  • avoid offending medications
  • supportive care 
  • hydration to protect against renal failure
  • transfusions, folic acid
  • splenectomy and vitamin E (anti-oxidant) have
    been suggested but not been proven effective
  •  
  • because hemolysis is usually mild, drugs may
    be given if there is important indication 
  •  

16
A word about Heme-pigment induced ATN
 AKI from heme pigment, either from myoglobinuria
(rhabdo) or hemoglobinuria (intravascular
hemolysis) can cause ATN. Urine microscopy shows
pigmented granular casts.  Urine is red-brown in
color. Results from obstruction with
intratubular heme pigment casts, concurrent
volume depletion and ischemia.   FeNa is often
lt1 in contrast to typical ATN reflecting tubular
obstruction more than necrosis. 
17
What doesnt fit . . .
  • Expect his H/H to be lower, especially with lack
    of reticulocyte response
  •  
  • Expect recovery
  •  
  • Expect greater indirect bilirubin  (initially
    elevated but then predominance of direct
    bilirubin) 
  •  
  • Retic profile was not elevated, but this may have
    been related to drug-induced marrow suppression 

18
References
Rose, Burton David.  Pathophysiology of Renal
Disease.  McGraw-Hill, Inc.  1987,
1981. Beutler, E. Study of glucose-6-phosphate
dehydrogenase history and molecular biology.
Am J Hematol. 1993 Jan42(1)53-8. Sarkar, S,
Prakash, D, Marwaha, RK, et al. Acute
intravascular hemolysis in blucose-6-phosphate
dehydrogenase deficiency. Ann Trop Paediatrics.
1993 13391. utdol.com
Write a Comment
User Comments (0)
About PowerShow.com